Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Shargorodsky, Marina ^a,b   Omelchenko, Elena ^a,b   Matas, Zipora ^a,b   Boaz, Mona ^a,b   Gavish, Dov ^a,b  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLUCOSE; METFORMIN;

ADULT; ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; AUGMENTATION INDEX; BLOOD PRESSURE METER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADIPONECTIN; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DOWN-REGULATION; FATTY LIVER; FEMALE; HEMODYNAMICS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; ISRAEL; LINEAR MODELS; MALE; METFORMIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 84861903068     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-61     Document Type: Article

References (35)

1. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005, 48:634-642. 10.1007/s00125-005-1682-x, 15747110.
2. Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 2004, 7:1498-1500.
3. Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 2005, 25:1045-1500. 10.1161/01.ATV.0000160613.57985.18, 15731489.
4. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, Cigolini M, Falezza G, Arcaro G. Relations between Carotid Artery Wall Thickness and Liver Histology in Subjects with Nonalcoholic Fatty Liver Disease. Diabetes Care 2006, 29:1325-1330. 10.2337/dc06-0135, 16732016.
5. Blaszik H, Ferrentino N, Forsell S, Stander D, Lidofsky S. A pilot study of metformin as treatment for nonalcoholic steatohepatosis. Gastroenterology 2005, 122:M1699.
6. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358:893-894. 10.1016/S0140-6736(01)06042-1, 11567710.
7. Sofer E, Boaz M, Matas Z, Mashavi M, Shargorodsky M. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism 2011, 60(9):1278-1284. 10.1016/j.metabol.2011.01.011, 21411114.
8. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865. UK Prospective Diabetes Study (UKPDS) Group.
9. de Aguiar LG K, Bahia LR, Villela N, Laflor C, Sicuro F, Wiernsperger N, Bottino D, Bouskela E. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 2006, 29:1083-1089. 10.2337/dc05-2146, 16644641.
10. Jager J, Kooy A, Lehert PH, Bets D, Wulffele MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJM, Stehouwer CDA. Effect of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controled trial. J Intern Med 2005, 257:100-109. 10.1111/j.1365-2796.2004.01420.x, 15606381.
11. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabet Med 2003, 29:6S44-6S52.
12. Araki T, Emoto M, Teramura M, Yokoyama H, Mori K, Hatsuda S, Maeno T, Shinohara K, Koyama H, Shoji T, Inaba M, Nishizawa Y. Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin. Metabolism 2006, 55(8):996-1001. 10.1016/j.metabol.2006.03.008, 16839832.
13. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063. 10.1161/01.CIR.103.8.1057, 11222466.
14. Tan KCB, Xu A, Chow WS, Lam MCW, Ai VHG, Tam SCF, Lam KSL. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004, 89:765-769. 10.1210/jc.2003-031012, 14764794.
15. Störk S, Bots ML, Angerer P, Schacky C, Grobbee DE, Angermann CE, Seufert J. Low levels of adiponectin predict worsening of arterial morphology and function. Atherosclerosis 2007, 194:e147-e153. 10.1016/j.atherosclerosis.2006.11.044, 17239889.
16. Weber T, Auer J, O'Rourke MF, Kvas E, Lassnig E, Berent R, Eber B. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation 2004 Jan 20, 109(2):184-189.
17. Gomez-Marcos MA, Recio-Rodríguez JI, Patino-Alonso MC, Agudo-Conde C, Gomez-Sanchez L, Rodriguez-Sanchez E, Gomez-Sanchez M, Garcia-Ortiz L. Yearly evolution of organ damage markers in diabetes or metabolic syndrome: data from the LOD-DIABETES study. Cardiovasc Diabetol 2011, 10:9. 10.1186/1475-2840-10-9, 3036611, 21255408.
18. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001, 37:1236-1241. 10.1161/01.HYP.37.5.1236, 11358934.
19. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance. An integrated index of vascular function?. Circulation 2002, 106:2085-2090. 10.1161/01.CIR.0000033824.02722.F7, 12379578.
20. Shin JY, Lee HR, Lee DC. Increased arterial stiffness in healthy subjects with high-normal glucose levels and in subjects with pre-diabetes. Cardiovasc Diabetol 2011, 10:30. 10.1186/1475-2840-10-30, 3098149, 21492487.
21. Asmar RG, London GM, O'Rourke MF, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001, 38:922-926. 10.1161/hy1001.095774, 11641310.
22. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary?. Eur J Gastroenterol Hepatol 2003, 15:539-543.
23. Zhou G, Myers R, Li Y. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1167-1174. 209533, 11602624.
24. Montagnani M, Quon MJ. Insulin action in vascular endothelium: potential mechanisms linking insulin resistance with hypertension. Diabetes Obes Metab 2000, 2:285-292. 10.1046/j.1463-1326.2000.00092.x, 11225743.
25. Meaney E, Vela A, Samaniego V, Meaney A, Asbún J, Zempoalteca JC, Elisa ZN, Emma MN, Guzman M, Hicks J, Ceballos G. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol 2008, 35(8):895-903. 10.1111/j.1440-1681.2008.04920.x, 18346173.
26. Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M, Rees DA. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 2010, 95(2):722-730. 10.1210/jc.2009-1985, 19996308.
27. Kiyici S, Ersoy C, Kaderli A, Fazlioglu M, Budak F, Duran C, Gul OO, Sigirli D, Baran I, Tuncel E, Erturk E, Imamoglu S. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Res Clin Pract 2009, 86(1):44-50. 10.1016/j.diabres.2009.07.004, 19674806.
28. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001, 37:1344-1350. 10.1016/S0735-1097(01)01129-9, 11300445.
29. Huang Y, Fu JF, Shi HB, Liu LR. Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes]. Zhonghua Er Ke Za Zhi 2011, 49(2):139-145.
30. Joel E. Lavine and The TONIC Randomized Controlled Trial: Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents. JAMA 2011, 305(16):1659-1668. 10.1001/jama.2011.520, 3110082, 21521847.
31. Krakoff J, Clark JM, Crandall JP, Wilson C, Molitch ME, Brancati FL, Edelstein SL, Knowler WC. Diabetes Prevention Program Research Group. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring) 2010, 18(9):1762-1767.
32. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004, 19:537-544. 10.1111/j.1365-2036.2004.01888.x, 14987322.
33. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002, 51:1884-1888. 10.2337/diabetes.51.6.1884, 12031977.
34. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96:1723-1732.
35. Kim SG, Kim HY, Seo JA, Lee KW, Oh HJ, Kim NH, Choi CM, Baik SH, Choi DS. Relationship between serum adiponectin concentration, pulse wave velocity and nonalcoholic fatty liver disease. Europ J Endocrinol 2005, 152:225-231.